Lars Fruergaard Jorgensen, who has been CEO since 2017, will remain in the role until a new CEO is appointed, says the company.

More than a dozen lawsuits have been filed on behalf of weight-loss drug users who claim that popular weight-loss medications ...

The Danish drugmaker Novo Nordisk announced it has temporarily reduced the price of the weight-loss drug Wegovy for new customers as it attempts to limit sales of compounded versions of the medication ...

The Novo Nordisk Foundation has pledged up to DKK 380 million ($57.76 million) to the World Health Organization (WHO) to ...

Novo Nordisk announced Friday that it would part ways with its longtime CEO, who steered the company into an unprecedented boom time for weight-loss drugs. The Ozempic maker’s chief executive ...

May 16 (UPI) --Novo Nordisk announced Friday that CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday that Jorgensen will continue as CEO ...

STORY: Novo Nordisk employees applauded their ousted CEO Lars Fruergaard Jorgensen on Friday.The Danish maker of weight loss ...

Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of leadership was required amid fierce glucagon-like peptide 1 receptor ...

Novo Nordisk's chief executive, Lars Fruergaard Jørgensen, is stepping down by "mutual agreement" with the company's board. In a statement, Novo Nordisk said that finding a new CEO is in the best ...

Helping compensate for the funding shortfall is the Novo Nordisk Foundation, which has pledged up to 380 million Danish ...